DP
HRMY icon

Diadema Partners’s Harmony Biosciences HRMY Stock Holding History

Diadema Partners’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-150,000
Closed -$4.13M – 163
2025
Q3 		$4.13M Buy
+150,000
New +$5.17M 1.06% 34

Other funds holding HRMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Diadema Partners's HRMY Position: Q2 2026 in Review

Diadema Partners reduced its Harmony Biosciences (HRMY) stake by 71% in Q2 2026, selling an estimated $2.08M and leaving 26,864 shares worth $978K. The position accounts for 0.12% of the portfolio, ranked #105.

Diadema Partners first reported a position in HRMY in Q3 2025 and has held it in 4 quarters since. The position peaked at $2.6M in Q1 2026. 327 funds tracked by Wall St. Rank hold HRMY as of Q2 2026.

  • Diadema Partners held 26,864 shares of Harmony Biosciences worth $978K as of Q2 2026.
  • Diadema Partners sold 66,000 Harmony Biosciences shares in Q2 2026, an estimated $2.08M.
  • Harmony Biosciences made up 0.12% of Diadema Partners's portfolio in Q2 2026, its #105 holding.
  • Diadema Partners first reported a position in Harmony Biosciences in Q3 2025 and has held it in 4 quarters since.
  • Diadema Partners's Harmony Biosciences position peaked at $2.6M in Q1 2026.
  • 327 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2026.

Based on Diadema Partners's 13F filing for Q2 2026, filed 14 Aug 2026.